AIkido Pharma Inc
AIKI
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.53M
Close$
$5.90
65.6% upside
Current Fair Value
65.6% upsideUndervalued by 65.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $19.53 Million |
|---|---|
| Enterprise Value | $12.22 Million |
| Dividend Yield | $- (26.02%) |
| Earnings per Share | $-1.57 |
| Beta | 0 |
| Outstanding Shares | 18,068,269 |
Return
| Return on Equity | -149.66% |
|---|---|
| Return on Assets | -55.44% |
| Return on Invested Capital | 100.50% |
Valuation & Multiples
| P/E Ratio | -1.41 |
|---|---|
| PEG | -1.85 |
| Price to Sales | 0.45 |
| Price to Book Ratio | 3.56 |
| Enterprise Value to Revenue | 0.08 |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.65 |
| Debt to Equity | 0.64 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About AIkido Pharma Inc
CEO: Anthony Hayes AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and res...